IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$3.58
-0.09 (-2.45%)
▼
5d:
-15.17%
30d:
-17.32%
90d:
-20.44%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Accumulation
IRWD is down 15.2% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 281 OI. Call ratio: 92% View Scanner →
Strength: 10.0/10
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IRWD is down 15.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IRWD is down 15.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.34
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$7.66
53.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $3.58, which is considered oversold relative to its 30-day fair value range of $3.68 to $4.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.5) compared to its historical average (4.4). Remarkably, the market is currently pricing in an annual earnings decline of 17.2% over the next few years. This pessimistic expectation contrasts with the company's recent 1046.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $3.47, while resistance sits at $4.88.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.10 (+70.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IRWD is in a strong uptrend. Immediate support is located at $3.47, while resistance sits at $4.88.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.10 (+70.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.68 -
$4.42
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.4% below Wall St target ($6.10)
- WARNING: Recommendation downgraded due to -15.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.68 -
$4.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.47
Resistance Level
$4.88
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.49
Wall Street Target
$6.10
(+70.4%)
Revenue Growth (YoY)
158.9%
Earnings Growth (YoY)
1046.8%
Profit Margin
28.3%
Valuation Discount vs History
-17.2% cheaper
PE vs Historical
2.5 vs 4.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.2%
(market-implied from PE analysis)
1-Year Target
$3.22
(-10%)
2-Year Target
$2.90
(-19%)
3-Year Target
$2.61
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→4)
$4.62
(+29%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 32.1%)
$73.28
(+1947%)
Base:
(SPY PE: 2.5, Growth: 32.1%)
$8.25
(+131%)
Bear:
(PE: 2.1, Growth: 32.1%)
$7.02
(+96%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (6x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 5.92 | Current EPS (TTM): $0.62
Bull Case
$8.07
(+126%)
Analyst growth 100.0%, PE expands to 6.5
Base Case
$7.34
(+105%)
Market implied 100.0%, PE stable at 5.9
Bear Case
$2.50
(-30%)
Severe decline -20.0%, PE contracts to 5.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.5 to 4.4
Stabilization Target:
$6.34
(+77.0%)
PE Expansion Potential:
+77.0%
Share & Embed Analysis
Last updated: May 18, 2026 7:32 AM ET
Data refreshes hourly during market hours. Next update: 8:32 AM
Data refreshes hourly during market hours. Next update: 8:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander J Denner
SELL
6730800 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
